Myriad Genetics' Stock Drops on SCOTUS Decision; Analysts Mixed on Implications | GenomeWeb

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slid as much as 18 percent today following the decision by the US Supreme Court invalidating the company's patents covering the BRCA1 and BRCA2 genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.